Cagrilintide news

All news on Cagrilintide (also known as AM833): plants, production capacities, investments and involved companies.

6 November 2025
Novo Nordisk's CagriSema Reduces Blood Pressure and Inflammation, Lowers Heart Disease Risk
CagriSema shows potential in reducing blood pressure, inflammation, and heart disease risk, with ongoing trials to assess cardiovascular outcomes.
5 November 2025
Novo Nordisk Reports 12% Sales Growth in DKK, 15% at CER, and R&D Advances in First Nine Months of 2025
Operating profit rose 5% in DKK, 10% at CER. Obesity care sales up 37%. FDA approved Wegovy® for MASH. Novo Nordisk to acquire Akero Therapeutics. Full-year sales growth forecast at 8-11% CER.
16 September 2025
Novo Nordisk Advances Cagrilintide to Phase 3 Clinical Program After Positive Results
Cagrilintide shows significant weight loss and tolerability in trials, prompting further study in the RENEW phase 3 program for obesity treatment.

Who will be producing Cagrilintide in the future?

Find out with chemXplore Analytics